electroCore, Inc., a bioelectronic medicine company, engages in developing a range of patient-administered non-invasive vagus nerve (VNS) stimulation therapies for the treatment of various conditions in neurology, rheumatology, and other fields. The company is developing gammaCore, a prescription-only non-invasive VNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, which is a handheld delivery system for multi-year use prescribed on a monthly basis. The company was founded in 2005 and is headquartered in Basking Ridge, New Jersey.
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone973-290-0097
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$990,000.00
Profitability
Miscellaneous
Employees91
Next Earnings Date6/27/2019 (Estimated)
OptionableNot Optionable
electroCore (NASDAQ:ECOR) Frequently Asked Questions
What is electroCore's stock symbol?
electroCore trades on the NASDAQ under the ticker symbol "ECOR."
How were electroCore's earnings last quarter?
electroCore, Inc. (NASDAQ:ECOR) posted its quarterly earnings data on Tuesday, November, 13th. The company reported ($0.45) earnings per share for the quarter, hitting the consensus estimate of ($0.45). The firm had revenue of $0.15 million for the quarter. View electroCore's Earnings History.
When is electroCore's next earnings date?
What price target have analysts set for ECOR?
3 brokerages have issued 1-year price targets for electroCore's shares. Their predictions range from $20.00 to $23.00. On average, they anticipate electroCore's share price to reach $21.50 in the next year. This suggests a possible upside of 242.1% from the stock's current price. View Analyst Price Targets for electroCore.
What is the consensus analysts' recommendation for electroCore?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for electroCore in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for electroCore.
What are Wall Street analysts saying about electroCore stock?
Here are some recent quotes from research analysts about electroCore stock:
- 1. According to Zacks Investment Research, "Electrocore, LLC operates as a bio-electronic medicine company. It reseraches and develops therapeutic technologies based in neurology and rheumatology. Electrocore, LLC is based in NJ, United States. " (4/9/2019)
- 2. BTIG Research analysts commented, "Q3 report surprised us with revenue well below estimates (~$150K vs our ~$1M) but strong patient and physician demand. With over 4500 prescriptions in the quarter – and about 2000 scripts in October alone – there is clearly prescriber/patient enthusiasm for gammaCore. But early reimbursement wins are taking longer than expected to turn into sales. At this time almost all patients are receiving the device through sample and copay assistance programs, with important payor coverage catalysts slated for early 2019. With patients getting gammaCore for free at this point and then pushing insurers to eventually cover it, it is difficult to determine how prescribing trends may evolve as reimbursement becomes the norm and as ECOR eventually must require payment." (11/15/2018)
Has electroCore been receiving favorable news coverage?
News coverage about ECOR stock has been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. electroCore earned a daily sentiment score of 2.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an effect on the stock's share price in the immediate future.
Who are some of electroCore's key competitors?
Some companies that are related to electroCore include Viewray (VRAY), BioLife Solutions (BLFS), Semler Scientific (SMLR), Rockwell Medical (RMTI), Cutera (CUTR), Zynex (ZYXI), Edap Tms (EDAP), BioSig Technologies (BSGM), Fonar (FONR), Stereotaxis (STXS), Second Sight Medical Products (EYES), IRIDEX (IRIX), Soleno Therapeutics (SLNO), Helius Medical Technologies (HSDT) and Viveve Medical (VIVE).
What other stocks do shareholders of electroCore own?
Who are electroCore's key executives?
electroCore's management team includes the folowing people:
- Mr. Francis R. Amato, CEO & Director (Age 55)
- Mr. Joseph P. Errico, Co-Founder, Chief Science & Strategy Officer, Principal Investor & Director (Age 50)
- Mr. Glenn S. Vraniak, Exec. Officer (Age 56)
- Dr. Peter S. Staats, Sr. Exec. Advisor of Medical & Gov. Affairs (Age 55)
- Mr. Steven M. Mendez, Founder & CTO (Age 58)
When did electroCore IPO?
(ECOR) raised $64 million in an IPO on Friday, June 22nd 2018. The company issued 4,300,000 shares at $14.00-$16.00 per share. Evercore ISI and JMP Securities served as the underwriters for the IPO and BTIG was co-manager.
Who are electroCore's major shareholders?
electroCore's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Hodges Capital Management Inc. (2.37%), Bfsg LLC (0.06%) and Valeo Financial Advisors LLC (0.05%). Company insiders that own electroCore stock include Carrie Smith Cox, Francis R Amato, Global Health Innovation Merck, Joseph P Errico and Peter S Staats. View Institutional Ownership Trends for electroCore.
Which institutional investors are selling electroCore stock?
Which institutional investors are buying electroCore stock?
ECOR stock was purchased by a variety of institutional investors in the last quarter, including Bfsg LLC and Valeo Financial Advisors LLC. Company insiders that have bought electroCore stock in the last two years include Carrie Smith Cox, Francis R Amato, Global Health Innovation Merck and Peter S Staats. View Insider Buying and Selling for electroCore.
How do I buy shares of electroCore?
Shares of ECOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is electroCore's stock price today?
One share of ECOR stock can currently be purchased for approximately $6.2850.
How big of a company is electroCore?
electroCore has a market capitalization of $178.68 million and generates $990,000.00 in revenue each year. The company earns $-55,820,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis. electroCore employs 91 workers across the globe.
What is electroCore's official website?
How can I contact electroCore?
electroCore's mailing address is 150 ALLEN ROAD SUITE 201, BASKING RIDGE NJ, 07920. The company can be reached via phone at 973-290-0097 or via email at [email protected]
MarketBeat Community Rating for electroCore (NASDAQ ECOR)
MarketBeat's community ratings are surveys of what our community members think about electroCore and other stocks. Vote "Outperform" if you believe ECOR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ECOR will underperform the S&P 500 over the long term. You may vote once every thirty days.
